The one target company
Metis Precision Medicine is a B-Corp* founded with the vision of bringing powerful cancer therapies to patients in need. Metis owns the intellectual property of a suite of anti-Met monoclonal antibodies (mAbs), with different and unique mechanisms of action, and is currently seeking investors, biotech or pharmaceutical companies interested in acquiring the relevant platform technology on a global basis.
(*) A Benefit Corporation or B Corp is a type of company that voluntarily meets the highest standards of purpose, responsibility, and transparency. The B Corps stand out on the market from all other realities. They go beyond the goal of profit, and innovate to maximize their positive impact on communities, environment, and mankind. In this way, the business becomes a regenerating force for society and the planet.